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Background. Hemoﬁltration in the form of continuous ven­
ovenous hemoﬁltration (CVVH) is increasingly used to treat 
acute renal failure. Compared to hemodialysis, hemoﬁltration 
provides high clearances for large solutes but its effect on 
protein-bound solutes has been largely ignored. 
Methods. Standard clinical systems were used to remove test 
solutes from a reservoir containing artiﬁcial plasma. Clearances 
of the protein-bound solutes phenol red (CPR) and indican (CIN) 
were compared to clearances of urea (CUREA) during hemoﬁl­
tration and hemodiaﬁltration. A mathematical model was de­
veloped to predict clearances from values for plasma ﬂow Qp, 
dialysate ﬂow Qd, ultraﬁltration rate Qf, ﬁlter size and the ex­
tent of solute binding to albumin. 
Results. When hemoﬁltration was performed with Qp 150 
mL/min and Qf 17 mL/min, clearance values were CPR 1.0 ± 
0.1 mL/min; CIN 3.7 ± 0.5 mL/min; and CUREA 14 ± 1 mL/min. 
The clearance of the protein-bound solutes was approximately 
equal to the solute-free fraction multiplied by the ultraﬁltra­
tion rate corrected for the effect of predilution. Addition of Qd 
42 mL/min to provide HDF while Qp remained 150 mL/min 
resulted in proportional increases in the clearance of protein-
bound solutes and urea. In contrast, the clearance of protein-
bound solutes relative to urea increased when hemodiaﬁltra­
tion was performed using a larger ﬁlter and increasing Qd to 
300 mL/min while Qp was lowered to 50 mL/min. The pattern 
of observed results was accurately predicted by mathematical 
modeling. 
Conclusion. In vitro measurements and mathematical mod­
eling indicate that CVVH provides very limited clearance of 
protein-bound solutes. Continuous venous hemodiaﬁltration 
(CVVHDF) increases the clearance of protein-bound solutes 
relative to urea only when dialysate ﬂow rate and ﬁlter size are 
increased above values now commonly employed. 
. 
Increasing molecular size limits solute transport by 
diffusion more than solute transport by convection. 
Henderson et al [1, 2] established that the clearance of 
solutes with size ranging from about 500 to 15,000 D 
can therefore be increased by employing hemoﬁltration 
instead of hemodialysis. Clinical studies, however, have 
so far failed to establish that hemoﬁltration is more bene­
ﬁcial than hemodialysis over the long term. Hemodialysis 
thus remains the predominant modality for end-stage re­
nal disease (ESRD) treatment. Hemoﬁltration, however, 
is increasingly employed in the treatment of acute renal 
failure. In this setting, hemoﬁltration is usually prescribed 
as continuous venovenous hemoﬁltration (CVVH) or 
continuous venovenous hemodiaﬁltration (CVVHDF). 
It has been suggested, though not proven, that clearance 
of large solutes is particularly important when renal fail­
ure develops in patients with sepsis, shock, or other condi­
tions which precipitate multiorgan failure [3, 4]. Because 
they are continuous therapies, CVVH and CVVHDF 
may also facilitate control of extracellular ﬂuid volume 
in patients with acute renal failure, who often receive 
large amounts of intravenous ﬂuid and have low blood 
pressure. 
Remarkably, most studies of CVVH and CVVHDF 
have failed to consider the effect of these treatments 
on protein-bound solutes. The kidney clears many sub­
stances which are bound to plasma proteins and in 
particular to albumin. Such solutes accumulate in re­
nal failure and there is increasing evidence that some 
of them are toxic [5–8]. Protein binding limits con­
vective as well as diffusive transport of solutes across 
artiﬁcial kidney membranes. We have recently devel­
oped a model which describes the clearance of protein-
bound solutes during hemodialysis [9]. The current study 
examined the clearance of protein-bound solutes dur­
ing hemoﬁltration and hemodiaﬁltration. A mathemat­
ical model was developed to describe solute clearances 
and the predictions of this model were tested in vitro. 
We found that small protein-bound solutes are poorly 
cleared by hemoﬁltration. In particular, our results in­
dicate that CVVH may clear protein-bound solutes less 
effectively than intermittent hemodialysis and that the 
clearance of such solutes can be increased by adding 
dialysis to provide CVVHDF. Dialysate ﬂow rates much 
higher than those conventionally used in CVVHDF, how­
ever, are required to make the clearance of protein-
bound solutes approach the clearance of unbound 
solutes. 
METHODS 
Clearance measurements during vitro CVVH and 
CVVHDF 
CVVH. Clearances of phenol red, indican, urea, and 
creatinine were measured during CVVH in vitro. Fluid 
representing a patient’s plasma was placed in a continu­
ously stirred 1.0 L reservoir and CVVH was performed 
using a Prisma system (Gambro, Lakewood, CO, USA). 
The reservoir ﬂuid contained bovine albumin (Sigma 
A-7906) (Sigma Chemical Co., St. Louis, MO, USA) at 
4.0 g/dL and had electrolyte concentrations which ap­
proximated sodium 149 mEq/L, potassium 4.0 mEq/L, 
magnesium 2.0 mEq/L, calcium 2.5 mEq/L, and PO4 47.5 
mg/dL with the pH adjusted to 7.4. Reagent phenol red, 
indican, urea, and creatinine were added to the reservoir 
to provide concentrations of approximately 3.0 mg/dL, 
2.0 mg/dL, 120 mg/dL, and 12.0 mg/dL, respectively, at 
the beginning of each CVVH run. Replacement ﬂuid con­
tained electrolytes in the same concentrations as reser­
voir ﬂuid but no albumin or test solutes. CVVH was 
performed over 150 minutes (four runs) in the predilu­
tion mode using a Prisma M60 Set which includes a 0.6 
m2 kidney composed of AN69 hollow ﬁbers with wall 
thickness 50 lm. The “plasma” (reservoir ﬂuid) ﬂow rate 
set at 150 mL/min and ultraﬁltration and replacement 
ﬂuid ﬂow rates set equal at 16.7 mL/min. The ultraﬁltrate 
volume was measured at the end of each experiment. 
The free solute fraction was calculated as the average of 
the solute concentration in the efﬂuent line divided by the 
solute concentration in the reservoir in samples obtained 
at 10 and 150 minutes. Additional reservoir ﬂuid samples 
were obtained at 0, 10, 30, 60, 90, and 120 minutes for 
clearance calculations. 
CVVHDF. CVVHDF in vitro was ﬁrst performed us­
ing the Prisma system with the same kidney and with the 
same reservoir and replacement ﬂuids as used in CVVH 
experiments. The dialysate had the same composition as 
the replacement ﬂuid. The dialysate ﬂow rate was set 
at 41.7 mL/min while the plasma ﬂow was again set at 
150 mL/min and the ultraﬁltration and replacement ﬂow 
rates at 16.7 mL/min. The reservoir volume was increased 
to 2.0 L and CVVHDF was performed over 75 minutes 
(four runs). The total volume of ultraﬁltrate combined 
with dialysate was measured at the end of each experi­
ment. Batches of albumin-containing ﬂuid were puriﬁed 
by dialysis for 2 hours before test solutes were added for 
clearance experiments. This was done to reduce possi­
ble interference with solute binding to albumin by con­
taminants in the reagent albumin. The free fraction of 
each solute was calculated as the average of measure­
ments made at 5 and 75 minutes. Microcon YM-30 tubes 
(Millipore, Billerica, MA, USA) were used to obtain ul­
traﬁltrate from reservoir ﬂuid for these measurements, 
since ultraﬁltrate in the efﬂuent line was mixed with 
dialysate. Additional reservoir ﬂuid samples were ob­
tained at 0, 5, 15, 30, 45, 60, and 75 minutes for clearance 
calculations. 
To test the effects of a higher dialysate ﬂow and larger 
kidney size, in vitro CVVHDF was performed using a 
Fresenius D machine and F6 kidney (Fresenius, Gurnee, 
IL, USA). The F6 kidney provides a 1.3 m2 surface area 
composed of polysulfone hollow ﬁbers with wall thick­
ness 40 lm. As such, it provides KoA values for vari­
ous solutes which are approximately threefold greater 
than those provided by the Prisma M60 set, as further 
described in the results below. The dialysate ﬂow rate 
for CVVHDF experiments performed with the F6 was 
set at 300 mL/min while the plasma ﬂow was set at 
55 mL/min and the ultraﬁltration and ﬂuid replacement 
rates were again set at 16.7 mL/min. CVVHDF was per­
formed over 75 minutes (four runs). Solute free frac­
tions were measured as described above and samples 
were collected at 0, 15, 30, 45, 60, and 75 for clearance 
calculations. 
Chemical assays and clearance calculations. Creati­
nine was measured with a Beckman Creatinine Ana­
lyzer 2 and urea was measured using a commercial kit 
(1770-50) (ThermoDMA, Arlington, TX, USA). Indican 
was measured by high-performance liquid chromatog­
raphy (HPLC) (Agilent 1100) (Agilent, Palo Alto, CA, 
USA). Plasma samples were deproteinized by addition of 
900 lL of  methanol to 300 lL of  plasma. This method 
which is derived from that of Lagana et al [10] provided 
indican recovery of 102 ± 2% and phenol red recovery of 
108 ± 7% (four runs at 1.0 mg/dL and 1.5 mg/dL, respec­
tively). Samples of the resulting supernatant were assayed 
by ﬂuorescence detection (excitation 250 nm, emission 
410 nm) following processing on a C18 column using gra­
dients of 50 mmol/L ammonium formate and methanol 
as described by Lesaffer et al [11]. For CVVH and 
CVVHDF, phenol red was assayed using a method mod­
iﬁed from Hirata-Dulas et al [12] as previously described 
[9]. For CVVHDF with higher dialysate ﬂow, phenol red 
was measured by HPLC using the same protocol as for 
indoxyl sulfate but employing ultraviolet absorption at 
433 nm rather than ﬂuorescence for detection. Clear­
ance values were calculated from the best ﬁt slope of log 
values for concentrations and from measured reservoir 
volume corrected for the volume of samples removed. 
Clearance values for various treatments were com­
pared by one-way analysis of variance (ANOVA) with 
post hoc least signiﬁcant difference testing for multiple 
comparisons. 
Values for KoA for the M60 and F6 ﬁlters were deter­
mined in separate experiments in which dialysis was per­
formed without albumin in the reservoir. In these experi­
ments (three for each ﬁlter), the Fresenius D machine was 
used with the ultraﬁltration rate set at zero. For the M60 
ﬁlter, Qp was set at 200 mL/min and Qd at 300 mL/min 
and for the F6 ﬁlter, Qp was set at 300 mL/min and Qd 
at 500 mL/min. Clearances for urea, creatinine, indican, 
and phenol red were measured as the average of the arte­
rial venous (A-V) extraction multiplied by Qp measured 
four times over 30 minutes during each experiment. KoA 
values for each solute were then obtained from measured 
values for clearance, Qp, and Qd using the equation de­
scribed by Michaels [13]. 
Modeling the effect of protein binding on solute clearance 
Hemoﬁltration. The ﬂux of a solute which is not 
protein-bound during hemoﬁltration can be expressed as: 
Js = Jv · (1 − r) · Cp · c (equation 1) 
where Jv is the volume ﬂux, r is the reﬂection coefﬁcient 
for the solute, Cp is the solute concentration in plasma, 
and c is a factor which relates the solute concentration in 
plasma to the solute concentration in plasma water Cpw: 
Cpw = c · Cp (equation 2) 
This correction factor can be estimated as:
 
1
 
c = (equation 3) 
1 − h 
where h is the plasma protein concentration in g/dL 
multiplied by 0.011 [14]. To model the clearance of 
protein-bound solutes, we introduced two modiﬁcations 
in equation 1. First, the model was limited to small solutes 
for which r is effectively zero. For modern membranes, 
this includes solutes with size less than 2000 D, and thus 
includes almost all the protein-bound solutes which have 
been shown to accumulate in uremia [7, 15]. Second, it 
was assumed that only the portion of a solute not bound 
to protein is ﬁltered. The free solute concentration Cpf 
available for ﬁltration is thus represented by the follow­
ing: 
Cpf = f · Cp. (equation 4) 
where f is the fraction of solute which is not bound to 
proteins. Solute ﬂux can then be expressed as: 
Js = Jv · f · Cp · c (equation 5) 
When hemoﬁltration is performed with replacement 
ﬂuid added to the plasma before it enters the kidney, 
values for f , Cp, and c must be corrected for the effects 
of this “predilution.” The corrected solute concentration 
Cpc is: 
c Cp · QpC = (equation 6) p Qp + Qr 
and the corrected plasma protein concentration hc used 
to correct c is 
hp · Qp
hc = (equation 7) p Qp + Qr 
where Qp is the plasma ﬂow rate and Qr is the replace­
ment ﬂuid addition rate. The effect of predilution on f is 
less obvious but while predilution reduces the total solute 
concentration and protein concentration in proportion, it 
tends to increase the free fraction of a protein-bound so­
lute. The magnitude of this effect can be calculated assum­
ing that solute binding to albumin (or any other binding 
protein) is described by an association constant KA such 
that: 
Cp − CpfKA = (equation 8) Cpf · (Calb − Cp + Cpf ) 
This being the case, f can be expressed as: 
1
f = (equation 9) 
1 + (Calb − Cp + Cpf ) · KA 
and the value f c corrected for predilution is then given by 
equation 10 (see Appendix). 
The magnitude of this correction, which is hard to ap­
preciate by inspection of equation 10, is illustrated in Fig­
ure 1. It should be noted that the application of equations 
8 to 10 to  dialysis systems is based on the assumption that 
solute binding to protein is rapidly reversible. In using 
equation 10 to correct f for the effect of predilution, we 
assume that solute can dissociate from protein in the time 
it takes for plasma to ﬂow to the kidney from the point in 
the circuit where predilution ﬂuid is added. As revealed 
by Figure 1, the magnitude of this correction is small for 
the Qr/Qp ratios used in our experiments. 
During hemoﬁltration, the free solute concentration 
does not change as plasma passes along the kidney. Equa­
tion 5 therefore not only describes local values for ﬂux, ex­
pressed as solute transport and ﬂuid ﬂow per unit length 
along the kidney, but also can be used to calculate the 
total transport. Solute clearance is then given by: 
Cl = Jv · f · c (equation 11) 
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Fig. 1. The predicted effect of predilution with a replacement ﬂuid ﬂow 
rate (Qr) on  the free fraction (f c) of  protein-bound solutes. Curves are 
drawn for solutes whose free fractions are 0.10, 0.30, and 0.50 in plasma 
before the addition of replacement ﬂuid. f c increases as Qr increases 
relative to Qp. In  clinical practice with Qr less than Qp, the effect is 
modest but still large enough so that predilution causes less reduction in 
the clearance of protein-bound solutes than in the clearance of unbound 
solutes. 
with appropriate substitution of f c and cc if predilution is 
employed. 
Hemodiaﬁltration. In hemodiaﬁltration, solute con­
centrations vary along the length of the kidney and local 
ﬂuxes must be integrated to obtain total ﬂuxes. For these 
calculations, the kidney was considered to have a dimen­
sionless length of unity (0 ≤ x ≤ 1) with the plasma (or 
reservoir ﬂuid) inlet and dialysate outlet at x = 0 and 
the plasma outlet and dialysate inlet at x = 1, provid­
ing countercurrent ﬂow. The transfer of solute along an 
inﬁnitesimal length of the kidney during hemoﬁltration 
with countercurrent ﬂow dialysis must then satisfy the 
conservation of mass: 
−Js · dx = d (QpCp) = d (QdCd) 
(equation 12) 
and the transfer of ﬂuid must satisfy the conservation of 
volume: 
−Jv · dx = dQp = dQd (equation 13) 
where Qp is the volumetric ﬂow of plasma, Qd is the 
volumetric ﬂow of dialysate, Cp is the solute concentra­
tion in the plasma, and Cd is the solute concentration in 
the dialysate. The ﬂux of an unbound solute being trans­
ported by both diffusion and convection can further be 
described by the equations 14 to 17 as developed by Vil­
larroel, Klein, and Holland [16] and further elaborated 
by Waniewski et al [17]: 
Js = −k · (Cpw − Cd) + Jv · (1 − r) · C¯ (equation 14) 
where k is the membrane permeability, here expressed 
per unit length along the kidney, and 
C¯ = Cpw · (1 − u) + Cd · u (equation 15) 
with 
1 1 
u = − (equation 16) 
Pe exp (Pe) − 1 
where Pe, the Peclet number, is a dimensionless quan­
tity which represents the ratio of convective to diffusive 
transport and is given by: 
(1 − r) · JvPe = (equation 17) 
k 
The same modiﬁcations used in the case of pure 
hemoﬁltration were again used to adapt these equations 
to describe the ﬂux of protein-bound solutes. The model 
was restricted to small solutes for which sigma is effec­
tively equal to zero and the effective solute concentration 
on the plasma side was assumed to be the unbound solute 
concentration: 
Cpf = f · Cp (equation 18) 
When convection and diffusion are combined, f will 
vary along the length of the ﬁlter. The local value for f 
can be expressed as:  ( )2
1 4Cp,xCp,x − Calb,x − K1 A + Calb,x − Cp,x + KA + KA 
fx = 2Cp,x 
(equation 19) 
where KA is the association constant described in equa­
tion 8 and where Cp,x is the local solute concentration 
and Calb,x is the local albumin concentration which is in 
turn given by 
Calb,0 · Qp,0Calb,x = (equation 20) x f
Qp,0 − Jv · dx 
0 
In applying equations 8 and 19, we again assume that 
solute binding to protein is rapidly reversible. Speciﬁcally, 
we assume that the time required for solute to dissoci­
ate from albumin is short in comparison to the time re­
quired for plasma to transit the artiﬁcial kidney. In the cur­
rent study, the plasma transit time for experiments with 
the M60 kidney was approximately 20 seconds and the 
plasma transit time for experiments with the F6 kidney 
was approximately 60 seconds. We do not know the rate 
constants for the dissociation of phenol red and indican 
from albumin. Bilirubin, however, which is much more 
tightly bound, can dissociate from plasma albumin in a 
fraction of a second [18, 19]. Moreover, the blood transit 
time through the native kidney, which effectively removes 
many protein bound solutes, is less than 5 seconds. We 
therefore modeled protein bound solute clearance based 
on the assumption of rapid dissociation. To the extent 
that this assumption is untrue, the real clearance of pro­
tein bound solutes will be less than that predicted by the 
model. In the extreme case where no solute dissociates 
from albumin as plasma transits the kidney, the clearance 
of a protein bound solute would be equal to the clear­
ance of an unbound solute of the same size multiplied 
by f . 
To determine solute transport using the above equa­
tions, we must ﬁrst specify the proﬁle of ﬂuid transport 
along the kidney. The total ﬂuid transport must add up to 
the ultraﬁltration rate so that: 
1 
Qf = Jv · dx (equation 21) 
0 
For the current model, we assumed that the trans-
membrane hydraulic pressure difference changes linearly 
along the kidney and that Jv is proportional to the local 
value for transmembrane hydraulic pressure, fPx. In  this 
case, the local value for Jv is: [ ]
fP0 · (1 − x) + fP1 · xJv,x = 2 · Qf · 
fP0 − fP1 
(equation 22) 
where fP0 is the transmembrane pressure at the plasma 
inlet end of the ﬁlter and fP1 is the transmembrane pres­
sure at the plasma outlet end of the ﬁlter. 
Using values for f x provided by equations 19 to 22, 
equations 12 to 15 can be solved to yield total solute trans­
port in terms of the boundary variables Qp,0, Cp,0, Calb,0, 
Qd,1, and Qf and the constants KA and KoA. When predi­
lution is employed, the value Qr is also speciﬁed and the 
values: 
Cp,0 · Qp,0Cc = (equation 23) p,0 Qp,0 + Qr 
Calb,0 · Qp,0Cc = (equation 24) alb,0 Qp,0 + Qr 
and 
Qc = Qp,0 + Qr (equation 25) p,0 
are substituted for Qp,0, Cp,0 and Calb,0. For the present 
study, KA was calculated from measured values for f , Cp, 
and Calb using equations 4 and 8. Predicted values for so­
lute transport were obtained by solving the above equa­
tions using MATLAB (MathWorks, Natick, MA, USA). 
It should be noted that for the case of unbound solutes 
(KA = 0) and linear variation of Jv along the length 
of the ﬁlter, Waniewski et al [17] obtained an analytic 
solution to these equations. But we did not obtain an 
Table 1. Solute clearances during continuous venovenous 
hemoﬁltration (CVVH) 
Solute 
Free fraction 
% 
Measured 
clearance mL/min 
Predicted 
clearance mL/min 
Urea 
Creatinine 
Indican 
Phenol red 
100 ± 8 
100 ± 3 
25 ± 3a 
8.1 ± 1.0a,b 
14  ± 1 
14  ± 1 
3.7 ± 0.5a 
1.0 ± 0.1a,b 
16  ± 1 
16  ± 1 
4.3 ± 0.6a 
1.4 ± 0.2a,b 
Values are mean ± SD. Solute free fractions were assessed after predilution 
and clearance values were obtained with Qp ≈ 150 mL/min, Qr ≈ 17 mL/min, 
and Qf ≈ 17 mL/mn. 
aP < 0.05 vs. value for urea; bP < 0.05 vs value for indican. 
analytic solution which described the transport of 
protein-bound solutes. We are thus unable to provide a 
formula for clearance during CVVHDF analogous to the 
formula provided by equation 11 for CVVH or by the 
equations of Michaels [13] for hemodialysis using coun­
tercurrent ﬂow. 
Input values of the model described above include the 
transmembrane pressures fP0 and fP1 which are not 
routinely measured in clinical practice. In modeling clin­
ical CVVHDF, however, the simplifying assumption of 
a uniform value for fP along the length of the ﬁlter 
can be employed without introducing signiﬁcant error. 
For instance, in a separate experiment in which an ad­
ditional pressure transducer was added to the clinical 
system, we found that when CVVHDF was performed 
with the M60 at the ﬂows used in this study, fP0 was 
88 mm Hg and fP1 was 62 mm Hg. Use of a constant 
fP value instead of these measured values produced 
changes in predicted solute clearance values of less than 
1%. When CVVHDF was performed with the F6 and the 
ﬂows used in this study, measured values for fP0 and 
fP1 were 17 mm Hg and was 15 mm Hg. Use of con­
stant fP values instead of these measured values again 
produced changes in predicted solute clearance values of 
less than 1%. In general, variation of fP along the ﬁl­
ter will affect clearances only when rapid ultraﬁltration 
is combined with efﬁcient dialysis, and the effect of fP 
variation on clearance will diminish as solute binding in­
creases. It should be noted that in such cases the pressure 
drop along the kidney may not be linear, as ultraﬁltration 
simultaneously decreases blood ﬂow and increases blood 
viscosity. 
RESULTS 
Clearances measured during CVVH in vitro are sum­
marized in Table 1. Clearance values for the unbound 
solutes urea and creatinine averaged 14 ± 1 mL/min. 
Clearance values for the protein bound solutes were 
much lower, averaging 3.7 ± 0.5 mL/min for indican and 
1.0 ± 0.1 mL/min for phenol red. The measured values 
Table 2. Solute clearances during continous venovenous 
hemodiaﬁltration (CVVHDF) with dialysate ﬂow less than plasma 
ﬂow 
Free Fraction Measured Predicted 
Solute % clearance mL/min clearance mL/min 
Urea 100 ± 1  45  ± 2a 52 ± 2 
Creatinine 101 ± 1  42  ± 3a 51 ± 2 
Indican 18 ± 5b 10 ± 2a,b 9 ± 2b 
Phenol red 6.4 ± 0.9b,c 2.7 ± 0.3a,b,c 2.9 ± 0.4b,c 
Values are mean ± SD. Solute free fractions were assessed after predilution 
and clearance values were obtained using an M60 ﬁlter with Qp ≈ 150 mL/min, 
Qd ≈ 42 mL/min, Qr ≈ 17 mL/min, and Qf ≈ 17 mL/mn. 
aP < 0.05 vs measured clearance during in vitro continuous venovenous 
hyperﬁltration (CVVH). 
bP < 0.05 vs. value for urea. 
cP < 0.05 vs. value for indican. 
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Fig. 3. The predicted effect of KoA on solute clearances during con­
tinous venovenous hemodiaﬁltration (CVVHDF) with Qd < Qp. The 
conditions represented are similar to those of our experiments with 
Qd ≈ 42 mL/min and Qf ≈ 17 mL/min except that the small effect 
of predilution is omitted for simplicity. As KoA increases, clearance of 
an unbound solute (green line) approaches the theoretic maximum of 
Qd plus Qf and the clearance of a solute which is 90% protein bound 
(purple line) approaches the theoretic maximum of 10% of Qd plus Qf. 
Near maximal clearance values are obtained with small ﬁlters as long 
as Qd is low. 
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were close to the values predicted by equation 11. Essen­
tially, the predicted clearance rate for unbound solutes is 
the ultraﬁltration rate corrected for the effect of predi­
lution. The predicted clearance rate for bound solutes 
is obtained by multiplying this value by the plasma free 
fraction, with a further correction for the effect of predi­
lution on the free fraction as described in the Methods 
section (equations 10 and 11) and Figure 1. 
Clearances measured during CVVHDF performed 
with the dialysate ﬂow lower than the plasma ﬂow are 
summarized in Table 2. These experiments were per­
formed using the maximal dialysate ﬂow rate attainable 
with a commonly used CVVHDF system. The clearance 
rates of all solutes were signiﬁcantly increased in com­
parison with values obtained during CVVH alone. Mea­
sured clearance values for the unbound solutes urea and 
creatinine averaged 45 ± 2 mL/min and 42 ± 3 mL/min, 
respectively. Clearance values for the bound solutes also 
increased but remained much lower than those for the un­
bound solutes. Overall, the proportional increase in clear­
ance observed with the addition of dialysate to CVVH 
was similar for the unbound and bound solutes, and av­
eraged approximately threefold. 
The ﬁnding that superimposing dialysis with Qd < Qp 
on hemoﬁltration increases the clearances of unbound 
and bound solutes in similar proportion is in accord 
with the predictions of the model. With dialysate ﬂow 
much lower than plasma ﬂow and with adequate mem­
brane permeability, the model predicts that the solute 
Length 
Fig. 2. Solute concentrations along the length of a dialyzer during con­
tinous venovenous hemodiaﬁltration (CVVHDF) with Qd < Qp. In  
each panel, dialyzer length is on the horizontal axis with the plasma in­
let and dialysate plus ultraﬁltrate outlet at the left (x = 0) and the plasma 
outlet and dialysate inlet at the right (x = 1). Solute concentration is 
on the vertical axis. The total plasma solute concentration (red line) is 
set equal to 1.0 prior to predilution and the dialysate solute concen­
tration (blue line) is set equal to 0.0 at the dialysate inlet. When there 
is protein binding, the concentration of unbound solute is depicted by 
the broken red line. The gradient driving diffusion is indicated by the 
shaded area. The top panel depicts the clearance of an unbound solute 
during CVVHDF performed with Qp ≈ 150 mL/min, Qf ≈ 17 mL/min, 
and Qr ≈ 17 mL/min predilution, Qd ≈ 42 mL/min, and KoA ≈ 150 
mL/min. The solute concentration in the slowly ﬂowing dialysate plus 
ultraﬁltrate stream approaches the solute concentration in the plasma 
entering the ﬁlter and the clearance is 49 mL/min. This is close to the 
theoretic maximum of 53 mL/min imposed by the sum of Qd and Qf 
corrected for the effect of predilution. The bottom panel depicts the 
clearance of a solute which is 90% bound to plasma protein. The so­
lute concentration in the dialysate plus ultraﬁltrate stream is limited 
by the free solute concentration in the plasma entering the ﬁlter and 
the clearance is 5.5 mL/min. The value is slightly higher than 10% of 
the unbound solute clearance because predilution increases the solute 
free fraction from 10% to 11%. The relative magnitude of the solute 
clearances is reﬂected by the size of the arrows on the left of the ﬁgure. 
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Fig. 5. The predicted effect of increasing Qd and KoA on solute clear­
ances during continuous venovenous hemodiaﬁltration (CVVHDF). 
The curves illustrate the clearance of an unbound solute (green line) 
and a solute which is 90% protein bound (purple line) as Qd and KoA 
are increased with KoA equal to twice Qd at every point. The clearance 
of both unbound and bound solutes is limited by the plasma ﬂow rate, 
Qp. But raising solute clearance to any desired fraction of Qp requires 
much larger values of Qd and KoA when the solute is protein bound 
Length than when the solute is unbound. The ultraﬁltration rate Qf, which is set 
at one third of Qp in this ﬁgure, has a signiﬁcant effect on the clearance 
of small solutes only when Qd and KoA are relatively low. Fig. 4. Solute concentrations along the length of a dialyzer during con­
tinuous venovenous hemodiaﬁltration (CVVHDF) with Qd > Qp. The 
plasma total solute concentration (red line) and free solute concentra­
tion (broken red line) and dialysate solute concentration (blue line) 
are depicted as in Figure 2. The top panel depicts the clearance of an 
unbound solute in CVVHDF performed with Qp ≈ 50 mL/min, Qf ≈ 
17 mL/min, and Qr ≈ 17 mL/min predilution, Qd ≈ 300 mL/min, and 
KoA ≈ 600 mL/min. Solute is rapidly removed from the plasma and the 
calculated clearance is 50 mL/min, which is the limiting value imposed 
by the plasma ﬂow. The bottom panel depicts the clearance of a solute 
which is 90% bound to plasma protein while other parameters remain 
the same. The gradient driving solute diffusion into the dialysate plus 
ultraﬁltrate stream is reduced by protein binding. Transport continues 
along the length of the dialyzer because the increased dialysate ﬂow 
keeps the level in the dialysate plus ultraﬁltrate compartment lower 
than the free level in the plasma. The bound solute clearance of 23 
mL/min is almost half the clearance of the unbound solute, and could 
be made to approach even closer to the plasma ﬂow by further increas­
ing Qd and KoA. 
concentrations in the mix of dialysate and ultraﬁltrate 
leaving the kidney will be nearly equal to the free solute 
concentrations in the plasma entering the kidney, as il­
lustrated in Figure 2. The clearance of each solute will 
thus approach the sum of the dialysate ﬂow and ultraﬁl­
tration rates multiplied by the free solute concentration 
at the kidney inlet. Solute clearances will fall below this 
theoretic maximum if the kidney has a low mass transfer 
area coefﬁcient, as shown in Figure 3. Dialysis experi­
ments performed without albumin yielded KoA values 
for the M60 set of 186 ± 12 for urea, 106 ± 6 for crea­
tinine, 108 ± 10 for indican, and 61 ± 6 for phenol red. 
In our CVVHDF experiments with Qd < Qp, values for 
KoA were thus greater than Qd. When this is the case, 
as further shown in Figure 3, an increase in kidney size 
would not signiﬁcantly increase solute clearances. When 
Qd < Qp, changes in Qp will likewise have little effect on 
clearance. Our model predicts, for example, that reducing 
Qp from 150 to 75 mL/min while Qd is maintained at 42 
mL/min would reduce the clearance of urea by less than 
15% and the clearance of indican and phenol red by less 
than 5%. 
Having found that superimposing dialysis with Qd < 
Qp on hemoﬁltration increases the clearance of bound 
and unbound solutes in nearly equal proportion, we 
sought a means to preferentially increase the clearance 
of bound solutes. The model predicts that this can be ac­
complished by increasing the dialysate ﬂow above the 
plasma ﬂow as long as membrane permeability is ade­
quate. The results of in vitro CVVHDF experiments per­
formed to test this prediction are summarized in Table 
3. The measured clearances of urea and creatinine, 52 
± 3 mL/min and 54 ± 3 mL/min, respectively, were only 
slightly greater than observed in the previous experiment. 
But the measured clearances of indican and phenol red, 
31 ± 2 mL/min and 10.2 ± 0.4 mL/min, respectively, were 
increased threefold. The ratio of bound to unbound so­
lute clearances was thus greatly increased, in accord with 
the predictions of the model. 
The solute concentration proﬁles associated with the 
increased clearance of bound solute when Qd is greater 
than Qp are depicted in Figure 4. Increasing the dialysate 
ﬂow above the plasma ﬂow reduces solute concentrations 
in the dialysate plus ultraﬁltrate compartment. The un­
bound solute diffuses readily into the large quantity of 
dialysate plus ultraﬁltrate, and its concentration rapidly 
approaches zero as the plasma ﬂows through the kid­
ney. Thus, for the unbound solute, transport is practi­
cally complete in the early part of the kidney and the 
Table 3. Solute clearances during continous venovenous 
hemodiaﬁltration (CVVHDF) with plasma ﬂow less than dialysate 
ﬂow 
Solute 
Free 
fraction % 
Measured 
clearance mL/min 
Predicted 
clearance mL/min 
Urea 
Creatinine 
Indican 
Phenol red 
105 ± 1 
99 ± 6 
16 ± 1b 
5.8 ± 0.7b,c 
52  ± 3a 
54  ± 3a 
31 ± 2a,b 
10.2 ± 0.4a,b,c 
53 ± 1 
53 ± 1 
27 ± 1b 
9.0 ± 0.9b,c 
Values are mean ± SD. Solute free fractions were assessed after predilution 
and clearance values were obtained using an F6 ﬁlter with Qp ≈ 55 mL/min, Qd 
≈ 300 mL/min, Qr ≈ 17 mL/min, and Qf ≈ 17 mL/min. 
aP < 0.05 vs. measured clearance during in vitro continous venovenous 
hemoﬁltration (CVVH) and CVVHDF with dialysate ﬂow less than plasma ﬂow. 
bP < 0.05 vs. value for urea. 
cP < 0.05 vs. value for indican. 
clearance approaches the plasma ﬂow rate. The concen­
tration proﬁle for the protein-bound solute is different. 
The gradient driving diffusion is reduced by protein bind­
ing even though the high dialysate ﬂow keeps the solute 
concentration in the combined dialysate plus ultraﬁltrate 
low. So the rate of solute transfer in the early part of the 
kidney is much lower than for the unbound solute. But 
as free solute diffuses through the membrane, bound so­
lute dissociates from protein, replenishing the low free so­
lute concentration available for diffusion and convection. 
The total concentration and the free concentration of the 
protein-bound solute fall gradually together as transport 
continues along the length of the kidney. In contrast to 
the result obtained when dialysate ﬂow is only a fraction 
of plasma ﬂow, the clearance of the protein-bound solute 
can now exceed the clearance of the unbound solute mul­
tiplied by the free fraction of the bound solute. Again, we 
are assuming that the time required for solute to disso­
ciate from the binding protein is short compared to the 
transit time of plasma through the kidney. 
To obtain a high relative clearance of protein-bound 
solutes during CVVHDF requires an increase in KoA as 
well as in Qd. Dialysis experiments performed without 
albumin yielded KoA values for the F6 dialyzer of 549 ± 
30 mL/min for urea, 353 ± 24 mL/min for creatinine, 371 
± 17 mL/min for indican, and 221 ± 13 mL/min for phenol 
red. In our CVVHDF experiments with Qd > Qp, esti­
mated KoAs were thus of approximately the same mag­
nitude as Qd. Theoretically, as long as KoA is adequate, 
the clearance of even a tightly bound solute can be made 
to increase arbitrarily close to the limiting value imposed 
by the plasma ﬂow, as illustrated in Figure 5. The ﬁgure 
shows modeled clearance values for an unbound solute 
and a protein-bound solute as Qd is increased from zero 
(pure ultraﬁltration) to greatly exceed Qp while the Qf 
remains constant and KoA increases with Qd. For  an un­
bound solute, the clearance at Qd = 0 mL/min is equal 
to Qf, and the clearance at low values for Qd is close to 
the sum of Qf and Qd, as  has been previously described 
[20–22]. As Qf is increased, the clearance of the unbound 
solute falls below the sum of Qf and Qd but still rapidly 
rises to approach Qp. The clearance proﬁle for a protein-
bound solute is much different. For low values of Qd, the 
clearance is close to the clearance of the unbound so­
lute multiplied by the fraction of the bound solute which 
is free in plasma. As Qd increases, the clearance of the 
bound solute increases more gradually than the clearance 
of an unbound solute, but keeps rising after the clearance 
of the unbound solute has reached the limiting value of 
Qp. It  should be noted that with high dialysate ﬂow, the 
transport of small solutes is accomplished largely by dif­
fusion, and turning ultraﬁltration on and off has only a 
minor effect on solute clearance. 
DISCUSSION 
The ﬁrst aim of this study was to assess the clearance of 
protein-bound small solutes during hemoﬁltration. Re­
sults showed that for a given protein-bound solute, the 
clearance is approximately the ultraﬁltration rate mul­
tiplied by the free solute fraction, corrected as neces­
sary for the effects of predilution on solute concentration. 
Protein-bound solutes are thus poorly cleared by conven­
tional CVVH. For instance, with an ultraﬁltration rate of 
30 mL/min, the predicted clearance of a solute which is 
90% protein bound is only 3 mL/min using postdilution 
and slightly less than 3 mL/min using predilution. 
The limitation imposed by protein-binding on solute 
clearance during hemoﬁltration is not hard to understand, 
but has received little attention. Hemoﬁltration was 
developed to improve the clearance of solutes whose 
diffusive transport during dialysis is limited by size [2]. 
Advocates of hemoﬁltration suggest that it is “more phys­
iologic” than dialysis because it removes solutes by a pro­
cess analogous to glomerular ﬁltration [23, 24]. In this 
view, the infusion of replacement ﬂuid takes the place of 
tubular reabsorptive function. But the absence of tubu­
lar secretory function, by which the normal kidney clears 
protein-bound solutes, is ignored. 
The second aim of this study was to assess the clear­
ance of protein-bound small solutes during hemodiaﬁl­
tration when dialysis is superimposed on hemoﬁltration. 
We found that as long as dialysate ﬂow is low compared to 
plasma ﬂow, the superimposition of dialysis on hemoﬁl­
tration increases the clearances of unbound and protein-
bound solutes in proportion, with the clearance rate for a 
given solute being approximately the free solute fraction 
multiplied by the sum of the ultraﬁltration and dialysate 
ﬂow rates. The hemodiaﬁltration prescriptions now com­
monly employed in the treatment of acute renal failure 
thus do not provide greater relative clearance of protein-
bound solutes than pure hemoﬁltration. 
The ﬁnal aim of this study was to identify means by 
which the clearance of protein- bound solutes can be 
increased relative to the clearance of unbound solutes. 
Table 4. Modeled solute clearances during renal replacement therapy 
Conventional CVVH CVVH CVVHDF CVVHDF Low efﬁciency Low efﬁciency 
Modality hemodialysis low Qf high Qf low Qd high Qd hemodialysis hemodialysis 
Qb mL/min 350 150 150 150 50 200 100 
Qf mL/min 24 20 40 20 20 4 4 
Qr mL/min 0  18  38  18  18  0  0  
Qd mL/min 600 0 0 20 300 100 200 
KoAurea mL/min 800 200 200 200 600 600 600 
Clurea mL/min 270 19 34 38 45 100 90 
Cl90%−bound mL/min 46 2.0 4.2 4.2 21 11 20 
Abbreviations are: CVVH, continuous venovenous hemoﬁltration; CVVHDF, continuous venovenous hemodiaﬁltraton. Modeled clearance values for urea (Clurea) 
and a hypothetical solute of the same size which is 90% protein-bound (Cl90%−bound) during renal replacement therapy. The various prescriptions would provide the 
same net ultraﬁltration if conventional hemodialysis was applied every other day and the other treatments were provided daily. The hematocrit was assumed to be 33% 
in each case. 
We found that this can be accomplished by increasing 
the dialysate ﬂow rate while restricting the plasma ﬂow 
rate during hemodiaﬁltration. Indeed, by adequately in­
creasing the dialysate ﬂow, the clearance of small protein-
bound solutes can be increased arbitrarily close to the 
clearance of small unbound solutes as long as kidney size 
is adequate. It should be noted that in current practice, 
when the dialysate ﬂow exceeds the plasma ﬂow, it also 
exceeds the ultraﬁltration rate. In this setting, the contri­
bution of ultraﬁltration to the transport of protein-bound 
solutes is relatively small, and the clearance of protein-
bound solutes is only slightly higher than that achieved by 
dialysis alone. The clearance of large solutes, in contrast, 
will still depend heavily on ultraﬁltration. 
The current model also reveals one alternate theoret­
ical means to increase the clearance of protein-bound 
solutes. As shown in Figure 1, if we assume solutes can 
rapidly dissociate from their binding proteins, the bound 
fractions will fall as the rate of predilution rises, and solute 
clearances can be increased during pure ultraﬁltration by 
using predilution and increasing the replacement and ul­
traﬁltration rates to greatly exceed the plasma ﬂow. Be­
cause replacement ﬂuid is more expensive than dialysate, 
however, this treatment would not be cost effective. 
Solute clearances have the same dependence on 
plasma and dialysate ﬂows during intermittent and 
continuous treatment. But hemoﬁltration and hemodi­
aﬁltration are most often prescribed continuously for 
the treatment of acute renal failure. Currently employed 
CVVH and CVVHDF regimens provide greater clear­
ances of large solutes than intermittent hemodialysis 
while providing equal or greater clearances of urea, de­
pending on the exact prescription [21, 25–27]. The current 
study suggests that in contrast, CVVH and CVVHDF 
may provide relatively low clearances of protein-bound 
solutes, as summarized in Table 4. The table presents 
clearance values for urea and a hypothetical solute PBS 
which is 90% bound to albumin. The clearance values 
have been calculated using the model described in the 
current study with the urea clearances corrected for the 
transport of urea out of red cells as described by Depner 
[28]. Intermittent hemodialysis with Qb ≈ 350 mL/min 
and Qd ≈ 600 mL/min is predicted to provide a PBS 
clearance of ≈ 42 mL/min while CVVH with Qf ≈ 17 
mL/min is predicted to provide a PBS clearance of only 
1.5 mL/min. Because volumes of distribution for protein-
bound solutes have not been measured, it is not pos­
sible to compare the theoretic effects of intermittent 
and continuous treatment on plasma solute concentra­
tions. Lesaffer et al [11] found that the concentrations 
of two solutes which are approximately 90% albumin 
bound fell much less than the concentration of urea dur­
ing hemodialysis treatment in vivo. If albumin-bound so­
lutes were restricted largely to the plasma space, their 
concentration would fall rapidly during dialysis despite 
the restriction imposed on clearance by albumin binding. 
The ﬁnding of Lesaffer et al [11] thus suggests that the 
volumes of distribution for protein-bound solutes may 
be considerably larger than the plasma volume, in which 
case CVVH with Qf ≈ 17 mL/min would lower plasma 
protein-bound solute concentrations less effectively than 
intermittent dialysis performed 4 hours every other day. 
As further shown in Table 4, the predicted clearance of 
unbound and bound solutes during CVVH treatment will 
increase approximately in proportion if the ultraﬁltration 
rate is increased to the recently recommended level of 35 
mL/kg/hour, or about 40 mL/min for an averaged size 
person [29]. Similar clearances of bound solutes would 
be achieved by shifting to CVVHDF and providing the 
same total amount of ﬂuid with half used as replacement 
ﬂuid and half used as dialysate. 
The restriction on the clearance of bound solutes rel­
ative to unbound solutes can be overcome only by using 
higher dialysate ﬂows and larger kidneys than are now 
commonly employed for CVVHDF, as further summa­
rized in Table 4. When high dialysate ﬂows are employed, 
the clearance of small molecules is accomplished almost 
entirely by diffusion and ultraﬁltration serves only to in­
crease the clearance of large molecules. The predicted 
dependence of protein-bound solute clearances on 
dialysate ﬂow and kidney size will be the same when in­
termittent treatment is prescribed. Recent studies have 
described the treatment of acute renal failure using 
hemodialysis for 8 to 12 hours daily [30, 31]. These “low 
efﬁciency” regimens often restrict the clearance of urea 
and other small unbound solutes by limiting the dialysate 
ﬂow rate [31]. Our model predicts that the clearance of 
protein-bound solutes would be greater if the clearance 
of unbound solutes were restricted by limiting the blood 
ﬂow rate while maintaining a higher dialysate ﬂow. For 
instance, as summarized in Table 4, the predicted clear­
ance of a 90% protein-bound solute would be 10 mL/min 
during low efﬁciency dialysis with Qb ≈200 mL/min and 
Qd ≈ 100 mL/min and 18 mL/min during low efﬁciency 
dialysis with Qb ≈ 100 mL/min and Qd ≈ 200 mL/min, 
while both regimens would provide nearly the same urea 
clearance. 
Several limitations of the current study should be ac­
knowledged. We have assumed that solute dissociation 
from albumin is rapid compared to the plasma transit time 
through the kidney. The efﬁcient extraction of protein 
bound solutes by the kidney suggests that this is indeed of­
ten the case, but measured dissociation rates are generally 
not available. Our model also assumes thorough solute 
mixing in both the plasma and the ultraﬁltrate/dialysate 
compartments. To the extent that mixing is not complete, 
the assumption that kidneys can be characterized by sin­
gle KoA values is not justiﬁed, and measured clearances 
will fall below predicted values. The magnitude of this 
error may be expected to increase when kidneys are em­
ployed using ﬂow rates for which they were not designed. 
In addition, the KoA values we used in modeling were 
obtained from measurements of clearance from albumin-
free solutions, and may have exceeded the KoA values 
obtained when kidneys were perfused with 4% albumin 
[32, 33]. 
Despite these limitations, the current model accurately 
predicted the extent to which clearances of protein-
bound solutes are restricted during hemoﬁltration and 
hemodiaﬁltration in vitro. Further studies are obviously 
required to determine whether the model predicts the 
behavior of protein-bound solutes in vivo. It should be 
noted that numerous solutes may compete for protein 
binding sites in uremic patients. The fractions of vari­
ous solutes which are bound to protein may therefore 
increase unpredictably as solute concentrations fall dur­
ing treatment. In general, clearance values would be ex­
pected to decline as protein-binding increases, but this 
requires testing in practice. A further interesting possi­
bility is that some uremic solutes bind to other blood 
constituents such as lipids or red cells in vivo. If binding 
is rapidly reversible, such solutes, like protein-bound so­
lutes, might be effectively cleared by the normal kidney 
but poorly cleared by hemoﬁltration. 
To the extent that they apply in vivo, our ﬁndings sug­
gest that conventional CVVH and CVVHDF regimens 
provide limited clearance of protein-bound solutes. Clin­
ical studies, as far as we are aware, have yet to exam­
ine this issue. A recent clinical study has shown that ad­
dition of hemoﬁltration at rates of 5 to 15 L per hour 
increases p-cresol clearance in patients receiving inter­
mittent hemodialysis [34]. The current model predicts this 
effect, but suggests that increases of the same magnitude 
could be more easily achieved by increasing dialysate 
ﬂow rate and dialyzer size. A broader question is whether 
the clearance of protein-bound solutes is clinically impor­
tant. Increasing evidence, however, links protein-bound 
solutes to uremic toxicity [6]. Limited clearance of such 
solutes could explain, at least in part, why the improved 
clearance of large solutes obtained with ultraﬁltration 
based therapies has so far not been associated with a dis­
cernable improvement in patient outcome [35–37]. Clin­
ical studies of modalities which increase protein-bound 
solute clearances will be required to address this ques­
tion. 
APPENDIX 
f c =  
c(c − 1)(1 − f ) − (q + 1)c f  (c f  − c + 1) + [c(1 − c)(1 − f ) + (q + 1)c f  (c f  − c + 1)]2 + 4(q + 1)c3 f (c f  − c + 1)(1 − f ) 
2c2 (1 − f ) 
(equation 10) 
where c = Cp/Calb and q = Qr/Qp. 
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